한글목차

동물 모델 시장은 2022년 19억 달러로 평가되었고, 2023년부터 2032년까지 연평균 복합 성장률(CAGR) 6.6%로 성장하여 2032년에는 36억 달러에 달할 것으로 추정됩니다.

백신은 감염병을 예방하고 통제하는 가장 효과적이고 경제적인 도구로, SARS-CoV-2의 급속한 확산, 임상 사례 간 편차, 결과 및 높은 사망률로 인해 세계보건기구(WHO)는 2020년 1월에 코로나19를 국제적으로 우려되는 공중보건 비상사태로 선언하고 2020년 3월에 팬데믹을 선언했습니다. 3월에 팬데믹을 선언하면서 약리학적 치료법과 백신 개발 경쟁이 시작되었고, 코로나19 백신 개발에서 신뢰할 수 있고 잘 특성화 된 실험 모델의 사용과 선택은 연구를 신속하게 진행하고 결과적으로 백신을 등록하고 사용할 수 있도록 하기 위해 중요했습니다. 2021년 국립의약품도서관의 보고에 따르면, 코로나19 연구에 참여한 동물 모델에는 마우스, 골든 햄스터, 흰쥐, 흰 족제비, 비영장류 동물, 돼지 등이 있으며, 302개 이상의 백신이 개발 중이고 그중 117개는 임상시험에 성공했다고 합니다. 이처럼 감염병 백신 시장 개척에 있어 동물모델의 사용 증가는 시장 성장에 크게 기여할 것으로 예상됩니다.

CRISPR(clustered regularly interspaced short palindromic repeats) 기술의 채택 증가는 동물 모델 시장의 주요 촉진요인으로 부상하고 있습니다. 과학자들이 동물을 포함한 다양한 생물의 DNA에 표적화된 변형을 가할 수 있게 함으로써 정확하고 효율적인 유전체 편집을 가능케 합니다. 이 획기적인 유전자 편집 도구는 유전학 및 생물 의학 연구 분야를 크게 발전시켰으며, 동물 모델 제작에 많은 응용 분야를 제공합니다. 또한, CRISPR 기술로 만든 동물 모델은 신약 발견에 있어 매우 중요한 역할을 합니다. 이 기술은 인간화된 면역체계를 반영하도록 DNA가 변형된 고도로 맞춤화된 마우스와 쥐를 제작하여 연구 시 정밀한 모델링이 가능할 뿐만 아니라 표적 검증과 효능 평가도 가능하게 합니다. 이 기술이 사용되기 이전에는 실험동물을 만드는 데 최대 18개월이 걸렸지만, 현재는 초기 동물 제작에 소요되는 시간이 3분의 1에서 2분의 1로 줄어들어 다른 전임상 동물 모델보다 비용 효율성이 높아졌습니다. 이처럼 CRISPR의 보급과 마우스 모델을 이용한 연구 증가는 시장 성장을 가속할 것으로 예상됩니다. 예를 들어, 미국의 의료 및 건강 R&D 투자는 2020년에 11.1% 증가한 2,451억 달러에 달했습니다. 의약품 개발 과정에서 마우스 모델을 효과적으로 사용하기 위한 연구 활동 증가는 시장 성장을 가속할 것으로 예상됩니다. 그러나 연구에서의 동물 사용에 대한 윤리적 지침은 동물 모델 시장의 성장을 억제할 것으로 예상됩니다.

세계 동물 모델 시장은 동물 유형, 용도, 최종 사용자, 지역으로 구분됩니다. 동물 유형별로는 쥐, 마우스, 기니피그, 토끼, 기타로 분류됩니다. 기타에는 제브라피쉬, 양서류 및 파충류, 햄스터, 친칠라, 스내치, 아르마딜로 등이 포함됩니다. 용도별로는 신약개발 및 연구개발, 기초연구, 기타로 나뉩니다. 기타에는 의료기기 개발, 생산 및 품질관리 등이 포함됩니다. 최종사용자별로는 제약-바이오 기업, 학술연구기관, 기타로 분류됩니다. 기타에는 의료기기 기업, CRO(임상시험수탁기관), 제조수탁기관 등이 포함됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter의 Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 동물 모델 시장 : 동물 유형별

• 개요
• 래트
• 마우스
• 몰모트
• 토끼
• 기타

제5장 동물 모델 시장 : 용도별

• 개요
• Drug Discovery 및 연구개발
• 기초 연구
• 기타

제6장 동물 모델 시장 : 최종사용자별

• 개요
• 제약 및 바이오 기업
• 학술연구기관
• 기타

제7장 동물 모델 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 호주
  • 인도
  • 한국
  • 기타
• 라틴아메리카/중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10개 기업의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Charles River Laboratories
• Inotiv, Inc.
• Genoway S.A.
• Hera Biolabs
• Crown Bioscience Inc.
• Ozgene Pty Ltd.
• Taconic Biosciences
• The Jackson Laboratory.
• Trans Genic Inc.
• Janvier Labs, LLC

영문목차

According to a new report published by Allied Market Research, titled, "Animal Model Market," The animal model market was valued at $1.9 billion in 2022, and is estimated to reach $3.6 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032.

Vaccines are the most effective and economical tools in preventing and controlling infectious diseases. Owing to the rapid spread of SARS-CoV-2, the variability among clinical cases, their outcomes, and high mortality rates, a race to find pharmacological treatments and vaccines was initiated once the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern in January 2020 and a pandemic in March 2020. In context, of vaccine development for COVID-19, the use and choice of reliable and well-characterized experimental models were important for the rapid advancement of research and, consequently, the registration and availability of the vaccines. According to a 2021 report by the National Library of Medicines, animal models involved in the study of COVID-19 include mice, golden hamsters, ferrets, nonhuman primates, and pigs. More than 302 vaccines were under development, of which 117 of them have successfully entered clinical trials. Thus, increase in usage of animal models in the development of vaccines for infectious diseases is expected to contribute significantly in the growth of the market.

Increased adoption of CRISPR (clustered regularly interspaced short palindromic repeats) technology has emerged as a major driver of the animal model market. CRISPR technology allows for precise and efficient genome editing by enabling scientists to make targeted modifications in the DNA of various organisms, including animals. This revolutionary gene-editing tool has significantly advanced the field of genetics and biomedical research, offering numerous applications in the creation of animal models. Furthermore, animal models generated by CRISPR technology have been crucial in the discovery of new medicines. This technology generates highly customized mice and rats whose DNA has been altered to reflect a humanized immune system, which enables precision modeling in research as well as target validation and efficacy assessment. Prior to the use of this technology, it took up to 18 months to produce test animals, whereas now it takes anywhere from one-third to one-half the time to create a founder animal, making it more cost-effective than alternative preclinical animal models. Thus, rise in adoption CRISPR and increase in mouse model-based research are expected to drive the growth of the market. For instance, the U.S. medical and health research and development investment reached $245.1 billion in 2020, an 11.1% increase in 2020. Increase in research activities in the mice model to effectively use them in drug development process is expected to drive the growth of the market. However, ethical guidelines for the use of animals in research are expected to restrain the growth of the animal model market.

The global animal model market is segmented into animal type, application, end user, and region. On the basis of animal type, the market is categorized into rat, mice, guinea pigs, rabbits, and others. The others include zebrafish, amphibians & reptiles, hamsters, chinchillas, gerbils, and armadillo. By application, the market is divided into drug discovery & development, basic research, and others. The others include medical device development, and production & quality control. Depending on end user, the market is segregated into pharma & biotech companies, academic research institutes, and others. The others segment includes medical device companies, contract research organizations (CROs), and contract manufacturing organizations. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA

The key players that operate in the global animal model market are The Jackson Laboratory, Janvier Labs, LLC, Genoway S.A., Hera Biolabs, Crown Bioscience Inc, Ozgene Pty Ltd., Taconic Biosciences, Trans Genic Inc., Inotiv, Inc., and Charles River Laboratories.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the animal model market analysis from 2022 to 2032 to identify the prevailing animal model market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the animal model market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global animal model market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast

Key Market Segments

By Animal Type

• Rat
• Mice
• Guinea pigs
• Rabbits
• Others

By Application

• Drug discovery and development
• Basic research
• Others

By End User

• Others
• Pharma and biotech companies
• Academic research institutes

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• The Jackson Laboratory.
• Hera Biolabs
• Janvier Labs, LLC
• Inotiv, Inc.
• Charles River Laboratories
• Taconic Biosciences
• Crown Bioscience Inc.
• Ozgene Pty Ltd.
• Trans Genic Inc.
• Genoway S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Rise in usage of animal models in virology and infectious diseases
    • 3.4.1.2. Physiological similarity of humans and animals for drug testing
    • 3.4.1.3. Increase in adoption of CRISPR technology
  • 3.4.2. Restraints
    • 3.4.2.1. Availability of alternative testing methods
  • 3.4.3. Opportunities
    • 3.4.3.1. Growth opportunities in emerging markets

CHAPTER 4: ANIMAL MODEL MARKET, BY ANIMAL TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Rat
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Mice
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Guinea pigs
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Rabbits
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Others
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country

CHAPTER 5: ANIMAL MODEL MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Drug discovery and development
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Basic research
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Others
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: ANIMAL MODEL MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Pharma and biotech companies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Academic research institutes
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Others
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: ANIMAL MODEL MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Animal Type
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Animal Type
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Animal Type
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Animal Type
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Animal Type
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Animal Type
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Animal Type
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Animal Type
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Animal Type
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Animal Type
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Animal Type
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Animal Type
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Animal Type
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Animal Type
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. Australia
    • 7.4.5.3.1. Market size and forecast, by Animal Type
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. India
    • 7.4.5.4.1. Market size and forecast, by Animal Type
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Animal Type
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Animal Type
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Animal Type
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Animal Type
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Animal Type
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Animal Type
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Animal Type
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Charles River Laboratories
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Inotiv, Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Genoway S.A.
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Key strategic moves and developments
• 9.4. Hera Biolabs
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
• 9.5. Crown Bioscience Inc.
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
• 9.6. Ozgene Pty Ltd.
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
• 9.7. Taconic Biosciences
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Key strategic moves and developments
• 9.8. The Jackson Laboratory.
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
• 9.9. Trans Genic Inc.
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Janvier Labs, LLC
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio